source
- Novartis and Novo Nordisk see back-to-back cardiovascular trial failures, raising doubts for the fieldNovartis announced that its experimental heart‑protective therapy, pelacarsen, did not meet its primary endpoints in a seven‑year study designed to cut heart attacks and strokes by lowering lipopro…
- FDA grants de novo clearance to Powerful Medical’s AI tool for detecting severe heart attacks on EKGsThe U.S. Food and Drug Administration issued a de novo classification for Powerful Medical’s AI algorithm that analyzes electrocardiograms to identify severe heart attacks. This clearance allows th…